The government has once again re-opened the totemic cannabis debate and its Advisory Council is now reviewing the C classification barely two years after their last review (when it stayed at Class C).
Cannabis is still, of course, a controlled drug. Those caught in possession or with supplying it face up to 2 and 14 years in prison respectively. Re-classifying it to Class B would make no real practical difference.
The core question is not whether cannabis is harmful - it is - but rather how harmful is it in comparison with other illegal drugs?
The classification system ranks illegal drugs according to their risk to the individuals who use them and the wider harms to society (eg from crime). Therefore determining the correct class for cannabis is 'simply' a case of comparing the harms it causes (to the individual and society) with those of other illegal drugs and assigning it to one of the three classes - A,B or C.
In reality the debate is not that simple. This is because the role of the classification system has become muddied (sometimes politically) and there are unrealistic or inappropriate expectations of what reclassification will achieve. Will it:
- Deter more people from using cannabis?
- Deter more suppliers from dealing it?
- Reduce the damage to people experiencing associated health problems?
- Or reduce the harm to wider society?
It might not always be intuitive, but scientific evidence suggests the answer to all of these questions is 'No'. (See the UK Drug Policy Commission submission to the Advisory Council for further discussion).
There is no doubt the (illegal) drug issue and especially the relatively minor issue of cannabis classification has become a political football. It is making an informed and rational national drug policy debate based on scientific evidence very difficult.
This begs the question whether the mechanism we have for making decisions about the classification of controlled drugs is appropriate.
The government has indicated it is going to review the drugs Advisory Council this year. This could provide an opportunity to look wider at the involvement of ministers in the classification process.
For instance, drawing on the examples of the Bank of England monetary policy committee and the Independent Safeguarding Authority, there ought to be no reason why an independent (and appointed) body or committee could not be charged with deciding (not simply advising ) on the classification of controlled drugs, based as now, on a scientific assessment of the evidence.
Naturally, accountability for decisions to Parliament could be ensured, for example through a select committee and annual or bi-annual reporting.
It is unfortunate that the many sensible things in the government's drug strategy are being overshadowed by this totemic cannabis classification issue. We need to look at new approaches which would enable ministers to be detached from some of the ill-informed media and political rhetoric which fuels this debate.
Roger Howard is chief executive of the UK Drug Policy Commission